Latin American countries (LATAMC) represent a large fraction of patients treated for multiple myeloma (MM) worldwide. In order to understand the difficulty of access to anti-myeloma therapy in LATAMC, we designed this study that explores areas involved in the availability of drugs, such as health care systems, approval times, coverage of new agents, old drugs, use of generics, and the first-line treatments.
Roberto José Pessoa de Magalhães Filho, Edvan Crusoe, Eloisa Riva, Willen Bujan, Guilhermo Conte, Juan Ramon Navarro Cabrera, Diana Katerine Garcia, Guilhermo Quintero Vega, Jose Macias, Jose Willian Oliveros Alvear, Mercedes Royg, Lidiane Andino Neves, Jose Luis Lopez Dopico, German Espino, Douglas Rosales Ortiz, Zurelis Socarra, Dorotea Fantl, Guillermo J. Ruiz-Arguelles, Angelo Maiolino, Vania Tietsche de Moraes Hungria, Jean-Luc Harousseau, Brian Durie
Clin Lymphoma Myeloma Leuk. 2018 Aug 29. pii: S2152-2650(18)30361-6.